Enrolment Begins In Combo Dual Therapy Stent Pivotal Trial in Japan

The patient enrolment has been initiated in Japan in the pivotal trial of OrbusNeich's investigational Combo dual therapy stent ( Combo stent) employing a single Japan-US protocol conducted as a global clinical trial 'proof-of-concept' under the framework of the joint Japan-US Harmonisation by Doing initiative. The first patient was enrolled at Shonan Kamakura General Hospital, Japan, by Dr Shigeru Saito, the Vice Director of the hospital and Co-Principal Investigator of the study.

The randomised, multicentre HARMONEE (Harmonized Assessment by Randomized, Multi-centre Study of OrbusNEich's Combo StEnt) study is designed to enrol 572 patients at up to 50 sites in Japan and the US to support the company's planned application for Shonin approval in Japan and to meet the pilot trial requirements in the US patients presenting with ischaemic coronary disease and non-ST segment myocardial infarction (MI) will be randomised one-to-one to treatment with a Combo stent or an everolimus-eluting stent comparator.

The HARMONEE study design consists of three cohorts, each with equal number of patients receiving either the Combo or the control stent. The first cohort includes 30 patients who will undergo assessment by fractional flow reserve (FFR) and quantitative coronary angiography (QCA) at 12 months and optical coherence tomography (OCT) at six and 12 months. The second cohort consists of 110 patients who will undergo assessment by FFR, QCA and OCT at 12 months. The third cohort of 432 patients will undergo assessment by FFR and QCA at 12 months.

The study's primary endpoint is a comparison of clinically driven target vessel failure, target vessel MI or ischaemia-driven target vessel revascularisation (TVR) by percutaneous or surgical methods. All patients will undergo FFR or angiography to determine ischaemia-driven TVR.

According to OrbusNeich, the study will investigate the clinical performance of Combo, which combines drug eluting technology for control of neointimal proliferation along with endothelial progenitor cell (EPC) capture technology for promoting early endothelialisation. Combo is claimed to be the first dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation. This is delivered through the combination of pro-healing technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves full and complete dissipation by 90 days.

OrbusNeich's patented EPC capture technology promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

This article is tagged to:
Related sectors of this article: Medical Devices, Drug Delivery, R&D - Medical Devices, Cardiovascular, MIW
Geography: Japan, Hong Kong, United States

Access all of our latest analysis, data and forecasts - request a trial